The DigiCare-CHD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated the efficacy of a smartphone-based digital remote management platform compared to usual care in achieving dual goal attainment of blood pressure and LDL-cholesterol levels in patients with coronary heart disease following percutaneous coronary intervention.
Age 18-75 years
Diagnosis of Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS)
Status post-successful percutaneous coronary intervention (PCI).
Possession of a smartphone and ability to operate the application (independently or with caregiver assistance).
Heart Failure: NYHA Class III-IV or LVEF < 40%.
Severe hepatic dysfunction (ALT/AST ≥3xULN or Total Bilirubin >1.5 mg/dl)
Severe renal dysfunction (eGFR < 30 ml/min/1.73m² or requiring dialysis)
Uncontrolled hypothyroidism (TSH >1.5xULN or >10 mIU/L, or unstable dosage within 6 weeks)
Beijing Anzhen Hospital
Lead sponsor